SALT LAKE CITY, April 6, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the appointment of Brian A, Meltzer, M.D. as Chief Medical Officer and Vice President of Business Development, effective April 1, 2015. Dr. Meltzer is a clinically trained physician with 15 years of expertise in the design and management of strategic growth programs and corporate ventures.
"Brian's career has encompassed all aspects of healthcare services and product development – from early development to market access," said Perseon Director Damian E. Dupuy, M.D. "His acumen as a strategic change agent has delivered a track record of success in creating new lines of business and fostering high functioning operational transformations. This expertise coupled with his medical background adds great value to our management team by providing a bridge between our corporate development goals and the clinical needs of our end users and markets. The role of Chief Medical Officer is an important new function for Perseon as we work to grow and maximize the value of our leading microwave ablation platform."
Dr. Meltzer joins Perseon from Purdue Pharma, L.P. where he was Executive Medical Director of the R&D Innovation and Licensing & Business Development. Previously, as a commercial trial leader for Janssen Healthcare Innovation, Dr. Meltzer developed and managed the company's Johnson & Johnson entry strategy, new business model development and investment plan for patient-related services. Earlier he held key roles in strategic corporate innovation and new venture groups in the health sciences for Johnson & Johnson Corporate Development and Ortho Clinical Diagnostics and was instrumental in the creation of the Urgent Care Center at Memorial Sloan-Kettering Cancer Center.
Dr. Meltzer completed his internship and residency with Internal Medicine, and fellowship in gastroenterology at New York Hospital-Cornell Medical Center. He holds an MBA in Health Care Administration from Baruch College, City University of New York; an M.D. in Medicine from State University of New York Upstate Medical University; and a B.S. in Biomedical Science from City University of New York.
Perseon Corporation, formerly BSD Medical Corporation, is a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy. Perseon's MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property and distributes its products in the United States, Europe and Asia.
Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 email@example.com